How to access Tarpeyo from Saudi Arabia, the named-patient import pathway, 2026

By Reserve Meds, Clinical and regulatory team. Last reviewed 2026-05-13.

A Saudi patient with primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression, to reduce proteinuria may receive a prescription for Tarpeyo (budesonide delayed-release capsules) from their treating nephrologist. Tarpeyo is FDA-approved in the United States and manufactured by Calliditas Therapeutics. It is a targeted-release corticosteroid administered by oral capsule. Local availability of Tarpeyo in Saudi Arabia can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through SFDA remains a legitimate route for the patient whose physician has already prescribed the drug.

This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.

The clinical situation

Tarpeyo is a targeted-release corticosteroid. Mechanism: an oral delayed-release formulation of budesonide that targets the ileal Peyer's patches, the proposed origin of pathogenic galactose-deficient IgA1. Dosing: 16 mg orally once daily in the morning for nine months, then taper, per FDA labeling. Baseline workup per FDA labeling includes baseline urinary protein-creatinine ratio, eGFR, blood pressure, glycemic status, and infection risk screen. Other important warnings include hypercorticism and adrenal axis suppression with prolonged use, immunosuppression and infection risk, and considerations during withdrawal and dose taper. Your nephrologist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.

Is Tarpeyo legally importable into Saudi Arabia?

Yes, through the Saudi Food and Drug Authority (SFDA) named-patient and personal-use import framework, coordinated with the treating facility's pharmacy. Saudi Arabia has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.

The SFDA named-patient route allows a Saudi-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.

How the pathway works, step by step

  1. Consultation with your treating nephrologist. The prescribing decision is clinical. Your nephrologist documents the indication, prior therapies where relevant, and rationale for Tarpeyo.
  2. Baseline screening. Baseline urinary protein-creatinine ratio, eGFR, blood pressure, glycemic status, and infection risk screen are confirmed and documented.
  3. SFDA named-patient application. Your nephrologist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
  4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from Calliditas Therapeutics's authorised distribution under DSCSA chain-of-custody.
  5. Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your nephrologist initiates therapy.

What documentation your physician needs

Your physician will typically need to provide:

  • A clinical rationale letter confirming diagnosis, prior therapies where relevant, and Tarpeyo as the indicated next step
  • Verification of their Saudi medical licence
  • A patient identifier, anonymised reference where privacy is preferred
  • Documented pre-treatment screening consistent with FDA labeling (see above)
  • The planned dosing regimen (16 mg orally once daily in the morning for nine months, then taper, per FDA labeling)
  • A monitoring plan covering infection screen, glycemic monitoring plan, and proteinuria and eGFR baselines

Reserve Meds provides a physician documentation kit tailored for IgAN oral therapy therapies, including the templates SFDA reviewers commonly request.

Typical costs and indicative timing

Reserve Meds gives you a drug-only reference range plus a transparent delivered quote at intake. As an illustrative composite case, the US cash-pay reference range for a typical month of daily dosing of Tarpeyo sits in an indicative 2026 band of approximately USD 13,000 to 17,000. International logistics, SFDA documentation handling, and concierge coordination add incremental cost. The delivered quote we issue at intake shows each line separately.

Indicative timing for first dose after cohort intake opens is approximately 2 to 5 weeks from the moment a complete application is submitted, assuming the documentation package is clean on first pass. Refills ship on a rolling cadence aligned to the dosing schedule.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort. All timelines are indicative, not guarantees.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Tarpeyo specifically, we provide:

  • Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
  • Documentation. Regulatory package tailored for your physician and for SFDA review, including IgAN oral therapy class templates.
  • Logistics. Internationally tracked shipment to your named dispensing facility with tamper-evident packaging.
  • Concierge case lead. A named point of contact for your family and your physician across the full case arc.

We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating nephrologist, and dispensing sits with the licensed Saudi pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.

Frequently asked

Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Saudi tertiary centers.

Will my private health insurance cover this? Cash-pay is the default posture. Some Saudi private insurers and CCHI-aligned plans reimburse named-patient imports on a case-by-case basis when the documentation package is strong. We supply documentation for your submission but do not process insurance claims.

What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major Saudi tertiary centers (King Faisal Specialist Hospital and Research Centre, King Abdulaziz Medical City, and KFSHRC Jeddah) have encountered. Our documentation kit is written for first-time applicants and tracks what SFDA reviewers commonly ask for.

Join the waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Tarpeyo coordination in Saudi Arabia.

Add me to the Tarpeyo waitlist

Composite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice. Reserved for you.